Community Oncology Alliance

 

Community Oncology Alliance
B

How Do We Define Quality Cancer Care?

By Community Oncology Alliance FEATURING Bo Gamble
November 4, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Featured Video

22:25
Novartis Oncology

The Importance of Dosing and Patient Adherence in HR+/HER2- mBC

Feat. N. McAndrew
2022 Community Oncology Advocacy Summit
27:01
Community Oncology Alliance

How To Engage Patients & Physicians as Advocates

Feat. C. Klock, L. Poiry
27:47
Community Oncology Alliance

Making It Local: How States Are Reforming Cancer Policy

Feat. N. Ferreyros, J. Lee
39:25
Community Oncology Alliance

Federal Cancer Care Policy: Updates From Capitol Hill

Feat. M. Atkins, T. Okon, H. Vyas
39:48
Community Oncology Alliance

Biosimilars: What Patients Need to Know

Feat. E. Randolph Broun, R. Saks
30:10
Community Oncology Alliance

Understanding the Impact of Disparities & Social Determinants of…

Feat. M. Kruczynski, A. Rahman, S. Sabo-Wagner
29:57
Community Oncology Alliance

How Do We Define Quality Cancer Care?

Feat. B. Gamble